Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

Optimal provision of needle and syringe programmes for injecting drug users: A systematic review.

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA.

Int J Drug Policy. 2010 Sep;21(5):335-42. doi: 10.1016/j.drugpo.2010.02.001. Epub 2010 Feb 26. Review.

PMID:
20189375
2.

Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.

Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D.

Addiction. 2010 May;105(5):844-59. doi: 10.1111/j.1360-0443.2009.02888.x. Epub 2010 Mar 2. Review.

PMID:
20219055
3.

Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.

Birkhead GS, Klein SJ, Candelas AR, O'Connell DA, Rothman JR, Feldman IS, Tsui DS, Cotroneo RA, Flanigan CA.

Int J Drug Policy. 2007 Oct;18(5):417-25. Epub 2007 Feb 20. Review.

PMID:
17854731
4.

The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis.

Kwon JA, Iversen J, Maher L, Law MG, Wilson DP.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):462-9. doi: 10.1097/QAI.0b013e3181a2539a.

PMID:
19387355
5.

The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings.

Islam M, Wodak A, Conigrave KM.

Int J Drug Policy. 2008 Dec;19(6):436-41. Epub 2007 Sep 4. Review.

PMID:
17766100
7.

HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway.

Miller M, Mella I, Moi H, Eskild A.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):373-9.

PMID:
12843749
8.

Select barriers to harm-reduction services for IDUs in eastern Europe.

Curth NK, Hansson LN, Storm F, Lazarus JV.

Cent Eur J Public Health. 2009 Dec;17(4):191-7.

9.

Client satisfaction and risk behaviours of the users of syringe dispensing machines: a pilot study.

Islam M, Stern T, Conigrave KM, Wodak A.

Drug Alcohol Rev. 2008 Jan;27(1):13-9.

PMID:
18034377
10.

Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.

Emmanuelli J, Desenclos JC.

Addiction. 2005 Nov;100(11):1690-700. Erratum in: Addiction. 2006 Apr;101(4):616.

PMID:
16277629
11.

Staff perceptions of syringe dispensing machines in Australia: a pilot study.

Islam MM, Conigrave KM, Stern T.

Subst Use Misuse. 2009;44(4):490-501. doi: 10.1080/10826080802344757.

PMID:
19283622
12.

Qualitative evaluation of a peer-based needle syringe programme in Vietnam.

Ngo AD, Schmich L, Higgs P, Fischer A.

Int J Drug Policy. 2009 Mar;20(2):179-82. doi: 10.1016/j.drugpo.2007.12.009. Epub 2008 Feb 1.

PMID:
18242971
13.

Needle and syringe sharing practices among injecting drug users in Tehran: a comparison of two neighborhoods, one with and one without a needle and syringe program.

Zamani S, Vazirian M, Nassirimanesh B, Razzaghi EM, Ono-Kihara M, Mortazavi Ravari S, Gouya MM, Kihara M.

AIDS Behav. 2010 Aug;14(4):885-90. doi: 10.1007/s10461-008-9404-2. Epub 2008 May 16.

PMID:
18483849
14.

Estimating the cost-effectiveness of needle-syringe programs in Australia.

Kwon JA, Anderson J, Kerr CC, Thein HH, Zhang L, Iversen J, Dore GJ, Kaldor JM, Law MG, Maher L, Wilson DP.

AIDS. 2012 Nov 13;26(17):2201-10. doi: 10.1097/QAD.0b013e3283578b5d.

PMID:
22914579
16.

Guidelines for better harm reduction: evaluating implementation of best practice recommendations for needle and syringe programs (NSPs).

Strike C, Watson TM, Lavigne P, Hopkins S, Shore R, Young D, Leonard L, Millson P.

Int J Drug Policy. 2011 Jan;22(1):34-40. doi: 10.1016/j.drugpo.2010.03.007. Epub 2010 Apr 22.

PMID:
20413288
17.

Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.

Wand H, Spiegelman D, Law M, Jalaludin B, Kaldor J, Maher L.

Addiction. 2009 Dec;104(12):2049-56. doi: 10.1111/j.1360-0443.2009.02704.x. Epub 2009 Oct 5.

PMID:
19804463
18.

Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.

Morissette C, Cox J, De P, Tremblay C, Roy E, Allard R, Stephenson R, Graves L.

Int J Drug Policy. 2007 May;18(3):204-12. Epub 2006 Oct 2.

PMID:
17689367
19.

A qualitative assessment of injection drug use and harm reduction programmes in Kabul, Afghanistan: 2006-2007.

Todd CS, Stibich MA, Stanekzai MR, Rasuli MZ, Bayan S, Wardak SR, Strathdee SA.

Int J Drug Policy. 2009 Mar;20(2):111-20. doi: 10.1016/j.drugpo.2007.11.022. Epub 2008 Jan 22.

PMID:
18207381
20.

Ability to access community-based needle-syringe programs and injecting behaviors among drug users: a cross-sectional study in Hunan Province, China.

Zhang L, Chen X, Zheng J, Zhao J, Jing J, Zhang J, Chow EP, Wilson DP.

Harm Reduct J. 2013 May 7;10:8. doi: 10.1186/1477-7517-10-8.

Supplemental Content

Support Center